Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Global Companion Diagnostics Market Report 2022: Sector to Reach $11.7 Billion by 2027 at a CAGR of 15.22% | ||
| By: PR Newswire Association LLC. - 30 Mar 2023 | Back to overview list |
|
|
DUBLIN, March 30, 2023 /PRNewswire/ -- The "Companion Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.  The global companion diagnostics market size reached US$ 5.0 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 11.7 Billion by 2027, exhibiting a CAGR of 15.22% during 2021-2027. Companies Mentioned
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor. Companion diagnostics refer to a combination of tests and therapies that provide essential information about corresponding therapeutic products to deliver safe and effective medical care. These diagnostics also offer an in-depth understanding of disease biology and the mechanism of action (MOA), which help healthcare professionals determine the potential side effects or risks of a therapeutic product on the patient. At present, companion diagnostics are extensively utilized in oncology to deliver targeted therapies and personalized medicines to patients. The growing prevalence of cancer, in confluence with the escalating demand for in-vitro diagnostics and targeted therapies, represents one of the key factors impelling the global companion diagnostics market growth. Apart from this, personalized healthcare (PHC) and precision medicine are also gaining traction in the treatment of cardiovascular, neurological, infectious and inflammatory diseases, which, in turn, is bolstering the growth of the market. Furthermore, the escalating demand for next-generation sequencing (NGS), the rising number of clinical trials and the increasing focus on the co-development of drugs and diagnostic technologies are contributing to the market growth. The introduction of new biomarkers, rising approvals of companion diagnostics and increasing collaboration between companies to develop novel companion diagnostic products are some of the other factors positively influencing the market growth. Currently, due to the spread of the coronavirus disease (COVID-19), diagnostic service providers are providing test services to healthcare providers. They are also utilizing companion diagnostics to detect the efficacy of COVID-19 drugs among patients undergoing oncology therapies. Key Market Segmentation: The publisher provides an analysis of the key trends in each sub-segment of the global companion diagnostics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product & service, technology, indication and end user. Breakup by Product & Service:
Breakup by Technology:
Breakup by Indication:
Breakup by End User:
Key Questions Answered in This Report: For more information about this report visit https://www.researchandmarkets.com/r/rqr82l About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets 
|
||
|
|
||
 | Back to overview list | |
View original content: